Study suggests how to develop intranasal vaccines for COVID-19 and flu
New research has explored the role of nasal bacteria to better develop intranasal vaccines for viruses such as COVID-19 and flu.
List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
New research has explored the role of nasal bacteria to better develop intranasal vaccines for viruses such as COVID-19 and flu.
SARS-CoV-2 Spike gene mutants may be developed into immunogens for new vaccines against COVID-19, a study in hamsters has shown.
The discovery that the TRPV4 gene regulates cartilage growth could lead to treatments for osteoarthritis and other cartilage diseases.
A potential drug to treat a subset of gastrointestinal stroma tumours (GIST) have been found to tackle intestinal tract cancer.
A nasal spray of the COVID-19 Vaccine Oxford/AstraZeneca was found to protect hamsters and monkeys against SARS-CoV-2 in an NIH study.
A team of researchers have reversed lung fibrosis in a mouse model, highlighting a new therapeutic target for pulmonary fibrosis.
Researchers have found a vulnerability in a developmental signalling pathway, presenting a target for paediatric low-grade glioma formation.
A research team have created a new strategy for developing an effective vaccine against a widespread form of tuberculosis.
Researchers have developed a new method that could make enzyme replacement therapy more efficient for Pompe disease treatment.
Scientists used artificial intelligence to identify 17 existing drugs that could kill SARS-CoV-2 in cells, including a dietary supplement.
Researchers have revealed a novel mechanism for platelet activation, suggesting a potential target for antithrombotic therapy.
A supercomputing method has revealed details of glycan “gates” on the SARS-CoV-2 Spike protein that open to allow virus entry and infection.
Researchers have used fruit fly larvae to explore how alpha-synuclein impacts the mitochondria, advancing the study of Parkinson’s disease.
Researchers identified the inhibitor JQ1 as a potential drug to improve immune response to CAR T-cell therapies in leukaemia patients.
Scientists found that changing interferon kappa levels altered the severity of psoriasis inflammation and cytokine production in mice.